Halbe Breite 1000x667 LETYBO v24

Croma-Pharma receives marketing authorisation for Letybo® in a further 12 European markets

Croma announced today that it has received marketing authorisation for Letybo®, the company’s botulinum toxin product, in 12 additional European markets. These include Belgium, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Luxembourg, Malta, Norway, Slovakia and Sweden. Letybo® will be launched in these countries in the coming weeks.


If you are a healthcare professional (HCP), please log in to see specific information about our products.



* fields are required